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Abstract
Following a decade-long scale up of malaria control through vector control interventions, the introduction of rapid diagnostic tests and
highly efﬁcacious Artemisinin-based Combination Therapy (ACT) along with other measures, global malaria incidence declined signiﬁcantly.
The recent development of artemisinin resistance on the Cambodia-Thailand border, however, is of great concern. This review
encompasses the background of artemisinin resistance in Plasmodium falciparum, its situation, especially in the Greater Mekong Sub-region
(GMS), and the responses taken to overcome this resistance. The difﬁculties in deﬁning resistance are presented, particularly the necessity
of measuring the clinical response to artemisinins using the slow parasite-clearance phenotype. Efforts to understand the molecular basis of
artemisinin resistance and the search for molecular markers are reviewed. The markers, once identiﬁed, can be applied as an efﬁcient tool
for resistance surveillance. Despite the limitation of current surveillance methods, it is important to continue vigilance for artemisinin
resistance. The therapeutic efﬁcacy “in vivo study” network for monitoring antimalarial resistance in the GMS has been strengthened. GMS
countries are working together in response to artemisinin resistance and aim to eliminate all P. falciparum parasites. These efforts are crucial
since a resurgence of malaria due to drug and/or insecticide resistance, program cuts, lack of political support and donor fatigue could set
back malaria control success in the sub-region and threaten malaria control and elimination if resistance spreads to other regions.
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Introduction
Along with AIDS and tuberculosis, malaria remains one of the
major killers, despite a decline in its incidence in recent years.
It was estimated that, in 2010, there were 219 million malaria
cases, and 660 000 deaths from malaria; Plasmodium falciparum
accounted for 91% of the overall cases [1]. P. falciparum is the
main cause of severe clinical manifestations and deaths.
Chloroquine and sulphadoxine–pyrimethamine were the main-
stays of antimalarial therapy for decades, but, by the 1990s,
resistance to both drugs had spread to almost all P. falcipa-
rum-endemic areas worldwide, resulting in rising malaria-re-
lated morbidity and mortality, particularly in Africa. As a result,
the treatment of falciparum malaria has become complicated,
and combination therapy is required, as it has been for
tuberculosis and AIDS. Since 2001, the WHO has recom-
mended artemisinin-based combination therapy (ACT), a
combined regimen of artemisinin and a longer-acting partner
drug, as the treatment of choice for falciparum malaria [2].
The recent emergence of P. falciparum strains with reduced
susceptibility to artemisinins in Pailin, western Cambodia, near
the south-eastern border of Thailand, raised the possibility
that these valuable drugs might already be losing their
usefulness. Even worse is the potential spread of resistance
beyond the Greater Mekong Sub-region (GMS, consisting of
Yunnan Province of China, Myanmar, Thailand, Laos, Cambo-
dia, and Vietnam), or de novo development of such resistance
elsewhere.
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Historical Patterns of Evolution and Spread
of Drug Resistance
P. falciparum resistance to chloroquine and sulphadoxine–
pyrimethamine ﬁrst developed on the Thailand–Cambodia
border in the late 1950s and 1960s, respectively. The spread
of resistant parasite strains elsewhere, including Africa, has
been well documented retrospectively with molecular mark-
ers of the resistance to each drug [3–5]. After chloroquine
and sulphadoxine–pyrimethamine failures, Thailand introduced
meﬂoquine as the ﬁrst-line drug for uncomplicated falciparum
malaria. To protect the lifespan of meﬂoquine, Thailand
imposed strict controls on its use. Nonetheless, meﬂoqu-
ine-resistant falciparum malaria outbreaks occurred during the
late 1980s and early 1990s in association with the inﬂux of
migrants for gem mining in Pailin. In 1995, Thailand replaced
meﬂoquine with artesunate–meﬂoquine. The same combina-
tion was the ﬁrst-line therapy in Cambodia from 2000 to
2012.
Current Therapy for P. falciparum Infection
Several ACT regimens are pre-qualiﬁed by the WHO and are
commercially available (http://apps.who.int/prequal/query/
ProductRegistry.aspx). By 2010, >80 endemic countries had
adopted ACT as the ﬁrst-line therapy [1]. The antimalarials
currently used by national control programmes in the GMS are
listed in Table 1.
The Early Indications of Diminishing Efﬁcacy
of ACTs in the GMS
It was not possible to strictly control antimalarial drug use in
Cambodia as had been done in Thailand, partly because of the
less developed public health system and the sparse infrastruc-
ture in rural areas. The initial plan was also to make ACTs
readily accessible in remote endemic areas, to rapidly reduce
the morbidity and mortality caused by malaria. As a result, in
Cambodia, artesunate, meﬂoquine and other ACTs were
available in the private sector without prescription or para-
sitological diagnosis. Clinical diagnosis was commonly used in
both public and private sectors. This situation has improved
only in the past 4–5 years; in the decade prior to that, these
were excellent conditions for the selection of artemis-
inin-resistant parasites.
The ﬁrst hints that the efﬁcacy of artemisinins might be
compromised emerged from studies of patients treated with
artesunate–meﬂoquine in western Cambodia and south-east-
ern Thailand in the 2000s [6–8], but it was not clear which of
the two drug components was responsible.
Artemisinin Resistance
Deﬁnition of resistance
The standard deﬁnition of antimalarial resistance has been
based on an assessment of the fraction of patients in a clinical
trial who fail treatment during a follow-up period of 28 days or
more. There are good reasons for this: for the ‘old’ drugs,
chloroquine and sulphadoxine–pyrimethamine, there were few
other tools, so resistance was acknowledged only after
treatment failures rose to levels high enough to dispel any
doubts.
Determination of artemisinin resistance in an ACT trial
involves both an artemisinin and its partner drug, and so
distinguishing the effects of artemisinins from those of the
partner drug is hampered by our dependence on a deﬁnitive
clinical therapeutic outcome. Drugs in the artemisinin class are
unique: they have a very short elimination half-life and the
ability to clear parasites extremely quickly [9]. The only
indicator of artemisinin action is the very rapid decline in
parasite burden observed after treatment, so a delay in
parasite clearance during the ﬁrst few days after ACT
treatment is considered to be suggestive of artemisinin
resistance.
TABLE 1. First line therapies against uncomplicated falcipa-
rum malaria adopted by the six GMS countries to replace
earlier drugs (chloroquine, SP and meﬂoquine monotherapy)
Country Regimen(s) Year implemented
Cambodia Dihydroartemisinin-Piperaquine,a
country-wide except Pailin
2012–present
Atovaquone-Proguanil,a in Pailin only 2012–present
Artesunate plus Meﬂoquinea 2000–2012
China Dihydroartemisinin-Piperaquine
Artesunate plus Amodiaquine
Artesunate plus Naphthoquineb
Artesunate plus Piperaquine
Laos, PDR Artemether-Lumefantrine 2005–present
Myanmar Artemether-Lumefantrine 2008–present
(with revision to add
primaquine 45 mgc in 2011)
Artesunate plus Meﬂoquine
Dihydroartemisinin-Piperaquine
Thailand Artesunate plus Meﬂoquine
(plus primaquine 30 mg)
1995–present
Atovaquone-Proguanil
(plus primaquine 30 mg) on the
southeastern border with
Cambodia (Trat and Chanthaburi
provinces) only.
2009–2013
Vietnam Artesunate monotherapy >20 years until 2009
Dihydroartemisinin-Piperaquine
(plus primaquine 0.5 mg base/kg)c
2009–present
aWith primaquine 45 mg according to policy, but not yet implemented due to
safety concern.
bNot part of WHO guidelines on malaria case management.
cIn practice, primaquine is not regularly prescribed.
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Parasite clearance as a measure of artemisinin efﬁcacy
Delayed parasite clearance is the basis for the current WHO
working deﬁnition of artemisinin resistance [10]. The propor-
tion of patients who are still parasite-positive on day 3 after
ACT treatment began in a trial with directly observed therapy
and standardized, quantitative microscopy is a parameter
currently used as an early signal of poor therapeutic response
to an artemisinin. According to the deﬁnition, if ≥10% of cases
still have detectable P. falciparum parasites 72 h after initiation
of ACT (‘day 3 parasitaemia’-positive), artemisinin resistance is
suspected. This requires veriﬁcation by standardized measure-
ment of the parasite clearance with oral artesunate in curative
monotherapy to conﬁrm/refute the presence of artemisinin
resistance in that endemic area [10].
On the basis of this deﬁnition, the WHO has conﬁrmed two
foci of artemisinin resistance so far: the Cambodia–Thailand
border area, and the northern part of the Thailand–Myanmar
border [11–13].
Since 2010, the day 3 parasitaemia-‘positive’ or slow-clear-
ance phenotype in association with different ACT regimens has
been observed at additional sites: south-western Myanmar,
southern Vietnam, and the Thailand–Myanmar border [14,15]
(Fig. 1). There has not been conﬁrmation of artemisinin
resistance at these sites. However, subsequent declines in
artesunate–meﬂoquine efﬁcacies are being observed in the
Thailand–Myanmar border areas [14].
Additional observations in Suriname showed a worrying
increase in the proportion of patients treated with arteme-
ther–lumefantrine who were day 3 parasitaemia-positive. An
investigation is ongoing for clariﬁcation at this northern
Amazon site, the ﬁrst site reported outside of the GMS (Jitan
et al., 61st Annual Meeting of the American Society of Tropical
Medicine and Hygiene, 2012, Abstract 1326).
The difﬁculties in measuring the response to artemisinins
with the parasite-clearance phenotype are manifold. The actual
clearance of parasites in each patient depends on the initial
parasitaemia, the synchrony and stage of the majority of the
parasites, and many host factors [16]. ‘Parasite-clearance rate’
is currently the primary tool used to standardize measurement
of the resistance phenotype [17,18]. For research purposes, a
precise assessment requires careful quantitative measurement
of the parasitaemia every 6–8 h over a period that can be as
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FIG. 1. Map of the Greater Mekong Sub-region showing Plasmodium falciparum-endemic sites with suspected (black dots) and conﬁrmed (black
stars) artemisinin resistance as of March 2013 (modiﬁed from Reference 14).
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long as 3 or 4 days [19]. In any individual patient, a standardized
approach has been proposed: the linear portion of the curve
that deﬁnes the half-life of the parasite numbers as they decline
[20]. This common parameter allows comparison of the
clearance rate from different regions or over a span of time.
In vitro artemisinin susceptibility
There is not yet a validated in vitro assay method that
correlates parasite susceptibility of P. falciparum to artemisi-
nins with ACT treatment outcomes or parasite-clearance
time, although experimental selection of resistance by drug
pressure in a rodent model has been attempted [21]. Scientists
are exploring modiﬁed assays that target the artemisinin
treatment to the very early ring stages of the development
cycle. These may allow the design of accurate in vitro methods
that can identify parasites with the slow-clearance phenotype
[22,23]. Validation of these methods is currently in progress.
Molecular basis of resistance
As a basis for the molecular study of artemisinin resistance, the
rate of parasite clearance following artemisinin therapy is the
only deﬁned phenotype that we can currently use. Despite the
complexity of that trait, scentists have shown that, in both
western Cambodia and western Thailand, the genes of the
parasites exercise strong control over their response to
artemisinins [13,24,25]. This insight made it worthwhile to try
to identify the speciﬁc gene or genes that control the clearance
phenotype.
The most straightforward way to deﬁne a marker of drug
resistance is to demonstrate that a parasite is much less
susceptible to the drug than expected in a laboratory-based test.
One can then investigate the genetic changes that are found in
those resistant parasites but are absent in closely related
parasites that are still sensitive to the drug at the usual low level
[26]. Unfortunately, a laboratory-based test that distinguishes a
slow-clearing from a rapidly clearing parasite is at an early stage
of development [22], so this approach is not yet an option.
A relatively complete reference genome has been available
for P. falciparum for >10 years [27], and comparing the
complete genomic sequences of a diverse group of parasites
allows the deﬁnition of important tools for analysis [28–31].
Using these tools, one can identify regions of the genome that
show signs of having been selected very recently in populations
of parasites subjected to heavy use of artemisinin-based drugs
[32]. Comparing such genomes with those of parasites that
have not been under that selective pressure should identify
candidate regions of the genome that contain genes respon-
sible for the phenotype. When applied to parasites from the
Thailand–Myanmar border, this approach identiﬁed a region
on chromosome 13 that ﬁts this deﬁnition [25].
An alternative approach involves comparison of the ge-
nomes of parasites that show the slow-clearing phenotype
with those of closely related parasites that do not, to identify
regions of the genome that are associated with the phenotype:
a genome-wide association study. In contrast to the ﬁrst
approach, one needs to correlate the phenotype with the
genotype in individual parasites. Using this method, Takala-
Harrison et al. have recently identiﬁed three regions on
chromosomes 10, 13 and 14 that show strong correlations
with slow clearance in populations from the GMS [33].
Although chromosome 13 was identiﬁed in both types of
genomic screen, these speciﬁc changes (single-nucleotide
polymorphisms (SNPs)) on chromosome 13 do not overlap
with the region described by Cheeseman et al. Even more
recently, a study that focused on the population structure of
four parasite groups that are all found in the area of Pailin,
Cambodia revealed that the ‘artemisinin-resistant’ parasites
constitute an unusual and genetically distinct subpopulation,
another indication that genetic factors strongly inﬂuence the
artemisinin resistance trait [34].
The identiﬁcation of speciﬁc changes in genes correlated
with the slow-clearing phenotype could greatly simplify
widespread surveillance for artemisinin-resistant parasites.
When these SNPs have been identiﬁed, they can be used to
develop an assay performed simply by collecting a small spot of
blood from an infected person on ﬁlter paper, and using basic
molecular methods to determine whether or not the parasites
in the sample carry the diagnostic SNP. For example, an early
method for detecting chloroquine-resistant parasites was
fundamental to understanding the changes in response to
chloroquine use and their extent [5]. Simple genetic markers
correlated with resistance to chloroquine and sulphadoxine–
pyrimethamine also allowed low-cost surveillance of the
geographical extent [35] and changes in the prevalence of
resistance [36], and identiﬁcation of the mechanisms that
underlie the resistance phenotype [37].
The slow-clearance phenotype could arise in parasites
elsewhere as a result of a different set of genetic changes, so
the correlation of these SNPs is currently being tested in other
parasite populations [33]. If the candidate SNP markers
suggested by Takala-Harrison et al. or newly identiﬁed by
others are validated, this could be a crucial step in tracking
artemisinin resistance in Southeast Asia, or elsewhere, when
there is suspicion of its emergence. Much earlier, in vitro
studies in French Guiana reported that SNPs in the ATPase6
gene were associated with lower susceptibility to artemether
in vitro [38], but those ATPase6 mutations could neither be
conﬁrmed in parasites from other regions [39] nor found to be
associated with the slow-clearing parasites from nearby
Suriname [40].
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There have been suggestions that some ‘traditional’ resis-
tance marker genes, pfmdr1 and pfmrp1, may be involved in
resistance to artemisinin, at least in a supportive role [41]. As
the artemisinin is only one component of ACTs, it is important
not to lose track of markers that may allow tracking of
resistance to the partner drugs. There are indications that
pfmdr1 copy number and particular alleles of pfmdr1 and pfcrt
are associated with reduced susceptibility to lumefantrine and
amodiaquine, two of the partner drugs commonly deployed
[42].
Resistance to Partner Drugs
The basis of the ACT design is the pairing of a short-lived
artemisinin with another antimalarial drug having a different
mode of action, and a much longer duration in the patient’s
body, the ‘partner drug’. Therefore, ACT efﬁcacy also depends
on the partner drug. Continuing use of an ACT in an endemic
community when there is signiﬁcant resistance to the partner
drug can be equivalent to exposing the parasites to artemisinin
monotherapy. Routine monitoring of ACT therapeutic efﬁca-
cies cannot distinguish whether diminishing efﬁcacy is attrib-
utable to the artemisinin or partner drug component, or both.
This difﬁculty can be partly solved by testing in vitro the
susceptibility of the partner drug of the ACT. The major
partner drugs being used in Thailand, Cambodia and neigh-
bouring countries are lumefantrine, meﬂoquine, and piperaq-
uine; all can be monitored with an in vitro assay [43,44].
Unfortunately, in vitro methods are technically and logistically
demanding, so they are not consistently used for monitoring
by malaria control programmes in the GMS.
Changes in the familiar loci, pfcrt and pfmdr1, are implicated
in resistance to meﬂoquine and lumefantrine. In Southeast
Asia, parasites with increased copy numbers of pfmdr1 have
been shown to be more resistant to meﬂoquine [45–47], and
the resistance is coupled with a particular SNP (184F) in
Cambodia [48]. However, in Africa, where meﬂoquine has
been little used, copy number variation in this gene is rarely
seen [49]. There is increasing evidence that the SNP K76 in
pfcrt and several codons in pfmdr1 are associated with lower
responsiveness to lumefantrine. Alleles of pfmdr1 that carry
the combination of codons 86N, 184F and 1246D are most
often implicated in lower responsiveness, both in Southeast
Asia and in the East African region [42,50–57]. There is
currently no information on mutations associated with resis-
tance to piperaquine, although its chemical similarity to
chloroquine and other 4-aminoquinolines such as amodiaquine
suggests that parasites with pfcrt alleles containing the 76T
codon and alleles of pfmdr1 that carry the 86Y, 184Y and
1246Y combination would be expected to be more resistant
to that class of drug. So far, molecular surveillance has not yet
been adopted for routine monitoring of antimalarial drug
resistance in the GMS.
Responses to Artemisinin Resistance
All foci of conﬁrmed and suspected artemisinin resistance are
currently in the GMS, with the exception of suspected sites in
the northern Amazon (Suriname and nearby areas). Intensiﬁed
malaria control in the Mekong was launched in 2008 to limit
spread, with the eventual goal of eliminating P. falciparum on
the Cambodia–Thailand border [58]. Updates of artemisinin
resistance evidence and response activities can be found on
the WHO Global Malaria Programme website (http://www.
who.int/malaria/areas/drug_resistance/updates/en/index.htm).
The WHO recommends routine antimalarial resistance
surveillance, and Mekong countries have been active in the
monitoring of ACT efﬁcacy by therapeutic trials through an
established sub-regional network [14]. However, low P. falci-
parum incidence has complicated the enrolment of sufﬁcient
study participants to reach the required sample size.
Application of molecular surveillance would be more practical
as a supplemental/alternative tool once a marker of artemisinin
resistance is identiﬁed. Africa has also been alerted to the
threat of artemisinin resistance, and improved monitoring is
being called for [59].
A number of other intensiﬁed control activities are needed,
such as prompt diagnosis, effective treatment and gametocyte
clearance, and vector control intervention. The ban on
artemisinin monotherapy, including with law enforcement, in
the Mekong is an example of an effort to reduce drug pressure
in order to prevent the selection of artemisinin resistant
parasites. Strategies targeting migrants and hard-to-reach
populations, such as to improve their accessibility to rational
therapy with ACTs, are important because of the potential of
these populations to serve as reservoirs and spreaders of
resistant parasites. The therapeutic and elimination strategies
deserve more detailed discussion.
Therapeutic strategy—use of schizontocidal drugs
Eurartesim (Sigma-Tau, Pomezia, Italy), a ﬁxed-dose dihyd-
roartemisinin–piperaquine combination, received European
Medicines Agency clearance in 2011. Dihydroartemisinin–
piperaquine was adopted as the ﬁrst-line therapy against both
falciparum and vivax malaria for Cambodia in 2012, except in
Pailin, where Malarone is the ﬁrst-line drug for P. falciparum.
Poor efﬁcacy of dihydroartemisinin–piperaquine has been
observed in Pailin and its neighbouring province of Pursat
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since 2009 [14]. The uncontrolled use of this ACT and
piperaquine alone in the private sector in Cambodia over a
decade before has been implicated.
A ﬁxed-dose combination (FDC) of pyronaridine and
artesunate, Pyramax (Shin Poong, Seoul, South Korea), was
given a positive scientiﬁc opinion by the European Medicines
Agency under Article 58 in 2012, and is being considered for
recommendation by the WHO. The combination has the
advantages of efﬁcacy against both P. falciparum and Plasmo-
dium vivax. It is considered to be safe in both adults and
children (≥20 kg), but liver function monitoring is recom-
mended [60,61]. It has not yet been adopted as the ﬁrst-line
antimalarial by any country in the GMS.
The artesunate–meﬂoquine combination used in the GMS
has taken the form of individual tablets of each drug
administered together. An FDC is now available under the
trade name Meﬂiam Plus (Cipla, Mumbai, India), and is
pre-qualiﬁed by the WHO [62]. The use of this FDC, which
offers better compliance, may increase in some parts of the
Mekong, such as Myanmar.
Malarone is a ﬁxed-dose combination of two antimalarial
agents, atovaquone and proguanil hydrochloride. It is a
non-ACT indicated for malaria prophylaxis and the treatment
of uncomplicated falciparum malaria. From 2009 to early 2013,
Malarone was used for the ﬁrst time on a large scale in
south-eastern Thailand adjacent to Pailin, with the intention of
temporarily reducing artemisinin drug pressure. Similarly,
Cambodia decided to adopt Malarone in Pailin in 2012 after
the dual failures of artesunate–meﬂoquine and dihydroartemis-
inin–piperaquine. However, high-level resistance to atovaquone
is well documented in vivo and in vitro [63]. A 1000-fold decrease
in susceptibility is caused by a single point mutation in the
mitochondrial cytochrome b gene (Y268S) [64]. Resistance to
cycloguanil, the active metabolite of proguanil, is conferred by
speciﬁc changes in the dihydrofolate reductase gene (dhfr)
(V16A, S108T, or I164L), but its synergy with atovaquone is not
thought to involve its antifolate speciﬁcity [65].
The limited availability of new drugs in the pipeline is a
challenge in dealing with artemisinin-resistant malaria. As
artemisinins are natural products, there have been serious
efforts to produce synthetic endoperoxides. The ﬁrst clinical
product of this sort was OZ277 (Rbx11160 or arterolane) [66],
an FDC of arterolane and piperaquine (Synriam; Ranbaxy,
Gurgaon, Haryana, India). OZ439 is another synthetic endo-
peroxide undergoing clinical trials [67]. The development of
these andother newdrugs has been reviewedelsewhere [68,69].
Malaria elimination
Elimination of the artemisinin-resistant P. falciparum parasites,
and eventually of malaria, is the ultimate goal of the coordi-
nated efforts to respond to artemisinin resistance in the
Mekong. The intensiﬁed malaria control over the past 4–
5 years has led to a very low malaria prevalence on the
Cambodia–Thailand border.
In Pailin, Cambodia, there were 1474 malaria cases (62%
P. falciparum) in 2009 and only 494 cases (118 or 24%
P. falciparum) in 2012 (source: Cambodian National Malaria
Control Programme). Across the border in Trat, Thailand, the
number of cases for the whole province dropped from 310
(35% P. falciparum) to 92 cases in 2012. Only 12 of these cases
(13%) were P. falciparum cases. In the adjacent province of
Chanthaburi, there were 646 cases in 2009 (11% P. falciparum)
and 152 cases in 2012, only six of these being P. falciparum
cases (4%) (Source: Thai National Malaria Control Program).
At present, a combination of tools with which to target
individual malaria cases for elimination is being considered. In
the absence of an effective vaccine, antimalarial therapies that
interrupt transmission or attack the gametocyte stage and
surveillance measures to detect asymptomatic, low-parasita-
emia cases are among the major issues to consider.
Gametocytocidal drugs. Declining artemisinin efﬁcacy means that
more parasites survive ACT treatment, enlarging the pool of
parasites that produce gametocytes, and accelerating the spread
of resistance. Primaquine has long been known to kill malaria
gametocytes, and supplementing ACT with primaquine could
substantially reduce transmission. TheWHOnow recommends
this strategy in low-transmission countries such as those in the
Mekong [2]. However, individuals who carry alleles of the
glucose-6-phosphate dehydrogenase (G6PD) gene with dimin-
ished activity may suffer serious haemolysis when treated with
primaquine. For this reason, the safety of the 45-mg single dose
of primaquine previously recommended has been questioned in
patients whose G6PD deﬁciency status is unknown [70]. In
practice, adding primaquine to ACT is not regularly done in the
Mekong. Recently, it was agreed that a 15-mg single dose of
primaquine to supplement ACT would be sufﬁciently effective
and safe, and this is the basis for the more recent WHO
recommendation [71].
Nonetheless, a test for G6PD deﬁciency should be
performed when possible to guide primaquine prescription.
Rapid tests are available for point-of-care adoption, but the
one product that has been cleared by the US Food and Drug
Administration is not feasible for use under ﬁeld conditions
[72]. A product with a user-friendly design for ﬁeld use, the
CareStart G6PD deﬁciency screening test, still needs improve-
ment in its accuracy, and is being subjected to further ﬁeld
clinical trials [73].
Currently, tafenoquine is the only other transmission-block-
ing drug that is still undergoing clinical trials. In terms of safety,
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it is a primaquine analogue, and can therefore similarly induce
haemolysis in G6PD-deﬁcient individuals. Its advantage is its
longer half-life, offering the possibility of administration as a
single-dose therapy [68].
Highly sensitive diagnostic tools. Asymptomatic parasite carriers
do not come to medical attention, and potentially form a
reservoir for new epidemics. New diagnostic methods that can
detect very low levels of parasitaemia are needed as a
surveillance tool as countries move towards elimination.
Designing PCR-based assays that are feasible for use in the
ﬁeld is one possibility [74,75].
Mass screening and treatment (MSAT). MSAT has been used for
outbreak investigation and elimination. A smaller-scale, more
manageable version of MSAT, focused screening and treatment
with PCR support, was conducted in western Cambodia in
2010 [76]. It was found to be a potentially useful tool for
identifying asymptomatic carriers of P. falciparum and providing
valuable epidemiological information, although with a high
price tag and logistical difﬁculties.
Mass drug administration (MDA). MDA is yet another strategy
whereby everyone in a deﬁned geographical area receives
treatment, irrespective of the presence of symptoms and
without malaria diagnosis. Currently, the WHO does not
encourage the use of MDA, because of its short-lived impact
on transmission and the likelihood that it will lead to
selection of drug-resistant genotypes. However, given the
urgent need for responses to artemisinin resistance, MDA
was revisited as a potential measure to eliminate P. falciparum
on the Cambodia–Thailand border [77]. Malarone–primaqu-
ine was considered as one of the drug choices for this
purpose. However, the safety proﬁle of Malarone and
primaquine given in combination has not been studied.
Treating a population with primaquine without screening
for G6PD deﬁciency status also raises ethical concerns.
Among the long list of other concerns are the unknown
boundary of the existing distribution of the artemisinin
resistant parasites and lack of a valid evaluation method with
which to measure the success of MDA operations [77].
Conclusion
Over the past decade, the world has witnessed signiﬁcant
declines in the numbers of malaria cases and associated deaths.
Improvements in case management, particularly with the
introduction of rapid diagnostics tests and highly efﬁcacious
ACTs, the scale-up of vector control interventions and other
preventive strategies are among key factors that have
contributed to this success. The recent emergence of
artemisinin resistance and its potential spread, however, have
threatened to reverse the accumulated gains.
Countries in the GMS are continuing their vigilance tracking
of ACT therapeutic efﬁcacy, and, for large areas in the GMS,
the goal is to eliminate P. falciparum. The GMS therapeutic
efﬁcacy surveillance has been strengthened, and case manage-
ment has been improved, along with other measures of malaria
control. However, there are several limitations of the existing
tools and strategies. In vivo therapeutic efﬁcacy monitoring is
becoming increasingly challenging, in part because of the
success of malaria control, which has led to difﬁculties in
enrolling an adequate number of study subjects. The potential
application of molecular surveillance is being explored, and we
have begun to understand artemisinin resistance mechanisms,
but much more work is required to identify and validate
molecular markers to serve as a surveillance tool.
As large areas in the Mekong are undergoing the transition
from standard malaria control to preparation for elimination,
control programmes need new, improved elimination tools
and strategies. Research to develop such tools, including drugs,
diagnostics, and surveillance strategies, is crucial. Globally, new
categories of drugs as potent as artemisinins would be ideal as
alternatives, now that artemisinin pressure is on the rise,
especially in Africa.
Strong political support, cross-border collaboration,
improved healthcare infrastructure, local economic develop-
ment and a long-term funding commitment are among the
important factors required to win our war against artemisinin
resistance.
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